We note, however, that the increase in levels of CA125 in other types of cancer, endometriosis, ovulation, other benign ovarian diseases, as well as its low sensitivity in early stages, limits its potential as a single biomarker for ovarian cancer screening. The gene discussed is MUC16; the disease is cancer.